Marshall Wace LLP have tried several times over the last years to short Genmab and have failed miserably. The 4th of december 2015 they announced that they finally have reduced their short in the company – after stubbornly have been entrenched in their position amidst an increase in share value of almost 50% in just 3 months.
Marshall Wace flagged their position in early september where the share price hovered around 600. Their liquidation price have been above 900. And with a position of around 300-360.000 shares that is a loss of a cool 100 million DKK. Ouch.